Breaking News Instant updates and real-time market news.

INCY

Incyte

$64.02

-19.05 (-22.93%)

08:00
04/09/18
04/09
08:00
04/09/18
08:00

Incyte price target lowered to $78 from $145 at Credit Suisse

Credit Suisse analyst Alethia Young lowered her price target for Incyte to $78 from $145 following news on ECHO-301 and as she removes epacadostat from valuation. The analyst reiterates an Outperform rating on the shares.

  • 23

    Apr

  • 12

    Jun

INCY Incyte
$64.02

-19.05 (-22.93%)

04/09/18
NOMU
04/09/18
NO CHANGE
Target $102
NOMU
Buy
Incyte price target lowered to $102 from $139 at Nomura Instinet
Nomura Instinet analyst Christopher Marai on Friday lowered his price target for Incyte to $102 after the Phase ECHO-301 trial of epacadostat and pembrolizumab in advanced metastatic melanoma was stopped. The analyst keeps a Buy rating on the shares. He tells investors to focus on the company's TKI pipeline.
04/09/18
RHCO
04/09/18
DOWNGRADE
Target $5
RHCO
Hold
NewLink Genetics downgraded to Hold at SunTrust on Incyte trial failure
As reported late last week, SunTrust analyst Peter Lawson downgraded NewLink Genetics (NLNK) to Hold from Buy and lowered his price target to $5 from $19. Lawson cites the announcement of negative results from the Phase 3 ECHO-301 of epacadostat + Keytruda in melanoma by Incyte (INCY), saying the data also implies a "significant negative read through for NewLink's IDO agent, indoximod". Lawson adds that the results have led him to remove melanoma from his NewLink model and also reduce the probability of success in pancreatic cancer, lowering the probability of adjusted peak sales from $415M to just $11M.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.
04/09/18
MSCO
04/09/18
NO CHANGE
Target $76
MSCO
Overweight
Incyte price target lowered to $76 from $142 at Morgan Stanley
Morgan Stanley analyst Thomas Smith lowered his price target on Incyte to $76 after removing epacadostat from his model following the announcement that the ECHO-301 trial failed to show benefit over PD-1 monotherapy in melanoma. However, Smith believes Incyte shares already reflected a significant amount of investor skepticism heading into the ECHO-301 data and he views the company as having one of the deepest pipelines in SMID-cap biotech, supported by the Jakafi base business in myelofibrosis, Iclusig royalties in Europe and royalties from baricitinib. Smith keeps an Overweight rating on Incyte shares.

TODAY'S FREE FLY STORIES

AVY

Avery Dennison

$92.38

-1.44 (-1.53%)

07:22
11/20/18
11/20
07:22
11/20/18
07:22
Recommendations
Avery Dennison analyst commentary  »

Avery Dennison emerging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

A

Agilent

$62.57

-2.42 (-3.72%)

07:22
11/20/18
11/20
07:22
11/20/18
07:22
Recommendations
Agilent analyst commentary  »

Agilent reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
11/20/18
11/20
07:20
11/20/18
07:20
General news
Futures point to continued selloff »

Stock futures are…

LYB

LyondellBasell

$92.77

-2.63 (-2.76%)

07:20
11/20/18
11/20
07:20
11/20/18
07:20
Upgrade
LyondellBasell rating change  »

LyondellBasell upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$58.24

-1.08 (-1.82%)

07:19
11/20/18
11/20
07:19
11/20/18
07:19
Recommendations
Ascendis Pharma analyst commentary  »

JPMorgan remains positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

NLSN

Nielsen

$25.24

-0.14 (-0.55%)

07:19
11/20/18
11/20
07:19
11/20/18
07:19
Hot Stocks
Nielsen board continues with review of strategic alternatives »

The Board of Directors is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGS

Medigus

$2.95

-0.09 (-2.96%)

07:18
11/20/18
11/20
07:18
11/20/18
07:18
Hot Stocks
Medigus to form new company for mini video cameras »

Medigus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AB

AllianceBernstein

$29.28

-0.37 (-1.25%)

07:17
11/20/18
11/20
07:17
11/20/18
07:17
Hot Stocks
AllianceBernstein announces offer to acquire Autonomous Research »

AllianceBernstein and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$25.24

-0.14 (-0.55%)

, IBM

IBM

$120.37

-1.23 (-1.01%)

07:16
11/20/18
11/20
07:16
11/20/18
07:16
Hot Stocks
Nielsen names David Kenny as CEO, effective December 3 »

The Board of Directors of…

NLSN

Nielsen

$25.24

-0.14 (-0.55%)

IBM

IBM

$120.37

-1.23 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 03

    Mar

GMDA

Gamida Cell

$9.50

-0.48 (-4.81%)

07:16
11/20/18
11/20
07:16
11/20/18
07:16
Initiation
Gamida Cell initiated  »

Gamida Cell initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

CODI

Compass Diversified

$15.11

-0.11 (-0.72%)

07:15
11/20/18
11/20
07:15
11/20/18
07:15
Conference/Events
Compass Diversified management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

  • 28

    Nov

07:15
11/20/18
11/20
07:15
11/20/18
07:15
General news
FX Update: There have been mixed themes »

FX Update: There have…

AAPL

Apple

$185.80

-7.62 (-3.94%)

07:14
11/20/18
11/20
07:14
11/20/18
07:14
Recommendations
Apple analyst commentary  »

Apple price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

STML

Stemline

$10.61

-0.76 (-6.68%)

07:14
11/20/18
11/20
07:14
11/20/18
07:14
Hot Stocks
Stemline announces EMA grants accelerated assessment for Elzonris MAA »

Stemline announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 21

    Feb

NJR

New Jersey Resources

$50.16

0.39 (0.78%)

07:12
11/20/18
11/20
07:12
11/20/18
07:12
Earnings
New Jersey Resources sees FY19 NFE $1.95-$2.05 »

NJR expects its regulated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BECN

Beacon Roofing

$27.74

0.12 (0.43%)

07:11
11/20/18
11/20
07:11
11/20/18
07:11
Recommendations
Beacon Roofing analyst commentary  »

Beacon Roofing price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NJR

New Jersey Resources

$50.16

0.39 (0.78%)

07:10
11/20/18
11/20
07:10
11/20/18
07:10
Earnings
New Jersey Resources reports Q4 EPS (18c), consensus (44c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BKI

Black Knight

$45.54

-4.23 (-8.50%)

07:09
11/20/18
11/20
07:09
11/20/18
07:09
Recommendations
Black Knight analyst commentary  »

Black Knight price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

CELC

Celcuity

$24.00

-0.7 (-2.83%)

07:08
11/20/18
11/20
07:08
11/20/18
07:08
Initiation
Celcuity initiated  »

Celcuity initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$14.38

-0.72 (-4.77%)

, BIIB

Biogen

$319.15

-4.86 (-1.50%)

07:08
11/20/18
11/20
07:08
11/20/18
07:08
Hot Stocks
Apellis appoints Adam Townsend as CCO »

Apellis (APLS) announced…

APLS

Apellis

$14.38

-0.72 (-4.77%)

BIIB

Biogen

$319.15

-4.86 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

BBY

Best Buy

$62.19

-4.22 (-6.35%)

07:07
11/20/18
11/20
07:07
11/20/18
07:07
Earnings
Best Buy sees Q4 EPS $2.48-$2.58, consensus $2.58 »

Sees Q4 Enterprise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

CLBS

Caladrius

$4.70

-0.18 (-3.69%)

07:06
11/20/18
11/20
07:06
11/20/18
07:06
Initiation
Caladrius initiated  »

Caladrius assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$62.19

-4.22 (-6.35%)

07:05
11/20/18
11/20
07:05
11/20/18
07:05
Earnings
Best Buy raises FY19 EPS view to $5.09-$5.19 from $4.95-$5.10 »

Consensus $5.11. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

RNSDF

Renault

$0.00

(0.00%)

, NSANY

Nissan

$0.00

(0.00%)

07:05
11/20/18
11/20
07:05
11/20/18
07:05
Periodicals
Renault board to discuss interim replacement for Ghosn, Reuters reports »

The board of French…

RNSDF

Renault

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OASM

Oasmia

$4.30

-0.64 (-12.96%)

07:05
11/20/18
11/20
07:05
11/20/18
07:05
Hot Stocks
Oasmia announces notice of allowance for nanotech patent from USPTO »

Oasmia announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.